

Haematologica  
HAEMATOL/2018/213314  
Version 3

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Lisa C. Holthof, Hilma J. van der Horst, Susan E. van Hal- van Veen, Ruud W.J. Ruiters, Fengzhi Li, Marijke Buijze, Morten N. Andersen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Henk M. Lokhorst, Sonja Zweegman, Richard W.J. Groen, and Tuna Mutis

Disclosures: none

Contributions: LCH, FL, NWCJD, HML, SZ, RWJG, and TM discussed conception and design. LCH, HJH, SEHV, RWJR, MB, MNA, HY, and JB performed research. LCH performed data analysis. LCH, NWCJD, SZ, RWJG, and TM performed data interpretation. LCH, RWJG, and TM wrote the manuscript. TM supervised the study.